Beijing, Hong Kong – April 16, 2019 – DCP Capital (“DCP”), a leading international private equity investment firm, today announced the final closing of the firm’s first Greater China focused US dollar private equity fund, DCP Capital Partners I (the “Fund”), which closed at its cap of over US$2 billion in commitments.
2019-04-16KKR & Co.’s former China heads have raised $2 billion for their debut private equity fund, according to people familiar with the matter. DCP Capital has committed 30 percent of the money for six deals in China, and the firm has also raised $500 million for a fund denominated in yuan that focuses on domestic Chinese investments.
2019-04-16KKR made an announcement that shocked the market yesterday. It said that David Liu, partner at KKR, Co-head of KKR Asia Private Equity, and CEO of KKR Greater China, has resigned. Together with another partner, Julian Wolhardt, the two will set up their own private equity firm.
2016-08-31On December 30th, 2021, DCP announced that it has officially signed the United Nations-supported Principles for Responsible Investment (UNPRI), promising to further implement the six Principles for Responsible Investment. As an internationally renowned private equity firm, DCP has long considered ESG impact on value creation, long-term company performance, and society as a whole since its foundation.
2021-12-30(November 29, 2021) DCP announced the completion of a strategic investment in Datong and has become the Company’s largest institutional shareholder. DCP indicated that it will work closely with Datong’s management team to create a new insurance ecosystem driven by product customization, demand matching, and a comprehensive service matrix to provide professional insurance services to Chinese consumers.
2021-11-29DCP announced the completion of a B round investment of multi-hundred million dollars in Hangzhou Valgen Medtech Co., Ltd. ("Valgen" or the “Company”), a leading innovator in the treatment of structural heart disease. The Company was incubated by DiNova Medtech (“DiNova”). The proceeds will be used to accelerate research and development in the treatment of mitral and tricuspid valve diseases.
2021-05-07DCP announced the completion of its investment in Adopt A Cow Dairy Co., Ltd. ("Adopt A Cow" or the “Company”), a rapidly growing dairy product company in China with a Direct-To-Customer (DTC) approach. The Company will use the proceeds from investment to build best-in-class dairy farms and processing facilities, introduce high-grade Australian dairy cow breed and upgrade its supply chain to ensure the safety and high quality of its products.
2021-04-19(Shanghai,March 11th,2021) Tonghua Dongbao Pharmaceutical Co., Ltd. (“Dongbao”), a portfolio company of DCP and a leading pharmaceutical company in China focused on diabetes treatment, announced a product in-license deal with Wuxi AppTec Co., Ltd. (“Wuxi AppTec”), a global leading R&D service provider in pharmaceutical, biotech and medical device industries.
2021-04-01DCP announced that it has co-led with CPE a US$300 million equity investment round in Hotwon Group . The investment will fund Hotwon’s robust data center pipeline to further capitalize on the rapid development of China's data center industry.
2020-12-15DCP, a leading international private equity firm, announced that it has reached an agreement to acquire a 9% stake in A-share listed Tonghua Dongbao Pharmaceutical Co., Ltd. from Dongbao Industrial Group Limited, for a consideration of approximately US$283 million.
2020-09-10Venus Medtech (Hangzhou) Inc. , DCP Capital and Qiming Venture Partners today jointly announced the completion of a definitive agreement to form Ascendum Capital Partners . Ascendum is dedicated to investing in innovative medical device companies in the global cardiovascular and lung disease treatment space. By leveraging Venus’s industry resources and the investment expertise of DCP Capital and Qiming Venture Partners, Ascendum aims to accelerate the R&D and commercialization of global leading
2020-07-16DCP Capital (“DCP”) today announced the completion of its investment in MFS Technology . DCP acquired a controlling stake in MFS in partnership with the Company’s senior management team, who invested significantly alongside DCP. MFS designs, prototypes, and manufactures custom-designed flexible printed circuit boards and rigid printed circuit boards used in electronic devices and equipment for leading global companies.
2019-12-26DCP Capital announced the completion of an equity investment in COFCO Meat Holdings Limited. Through this investment, DCP strengthened its strategic cooperation with COFCO Meat to continue building and upgrading the Company’s large-scale, modernized hog farms and meat processing facilities to meet the increasing demand for quality pork products in China.
2019-07-30DCP Capital, a private equity firm focusing on China, on Tuesday announced investment of $120 million through two rounds of convertible bonds to fuel the further growth of Sunpower Group Limited.
2018-09-12DCP Capital (“DCP”) today announced that it has invested a total of USD$120 million through 2 rounds of Convertible Bonds to support the continued growth of Sunpower Group Limited (“Sunpower” or the “Company”) (SGX: 5GD.SI).
2018-09-11DCP Capital (“DCP”) announced that it has reached a definitive agreement with Venus Medtech for an equity investment. The investment will facilitate Venus Medtech’s buildout of its sales network to establish the leading position in China’s transcatheter aortic valve replacement (TAVR) market.
2018-05-16